AMENDMENTS

In the Claims:

Please replace present claims 13, 15-16, 18-24 with the following claims 13, 15-16, 18-24:

13. (Thrice Amended) A method to elicit an antitumor immune response to prostate tumors in a subject, which method comprises

administering to said subject at least one active ingredient formulated for administration to said subject,

wherein said active ingredient is human prostate-specific membrane antigen (PSMA); or prostatic acid phosphatase (PAP); or mixtures of the foregoing; or

is a nucleic acid that generates PSMA or PAP, or mixtures of PSMA and PAP *in situ.*

15. (Amended) The method of claim 13 wherein said active ingredient is human PSMA.

16. (Amended) The method of claim 13 wherein said active ingredient is PAP.

18. (Amended) The method of claim 13 wherein said active ingredient is a nucleic acid that generates PSMA *in situ.*

19. (Amended) The method of claim 13 wherein said active ingredient is a nucleic acid that generates said PAP *in situ.*

20. The method of claim 13 wherein the active ingredient is encapsulated in liposomes and/or coupled to liposomes.

21. The method of claim 20 wherein said liposomes contain an adjuvant.

22. The method of claim 13 which further includes at least one adjuvant that enhances the antitumor immune response.

23. The method of claim 22 wherein said adjuvant is selected from the group consisting of Freund's complete adjuvant; alum; lipid A; monophosphoryl lipid A; *Bacillus Calmette-Guerin* (BCG) or other bacteria polysaccharides; saponins; detoxified endotoxin (DETOX); muramyl tripeptide or muramyl dipeptide or their derivatives; SAF1; lymphokines; cytokines; colony stimulating factors; nonionic block copolymers; and immune stimulating complexes (ISCOMS).

24. The method of claim 13 wherein said subject is afflicted with metastatic prostate cancer; and/or wherein said subject has been surgically treated to excise said tumor but is at risk for recurrence.